# Effect of MD1003 in Progressive Multiple Sclerosis (SPI2)

> **NCT02936037** · PHASE3 · TERMINATED · sponsor: **MedDay Pharmaceuticals SA** · enrollment: 642 (actual)

## Conditions studied

- Multiple Sclerosis

## Interventions

- **DRUG:** MD1003 100mg capsule
- **DRUG:** PLACEBO

## Key facts

- **NCT ID:** NCT02936037
- **Lead sponsor:** MedDay Pharmaceuticals SA
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-12
- **Primary completion:** 2019-11-15
- **Final completion:** 2020-04-23
- **Target enrollment:** 642 (ACTUAL)
- **Why stopped:** Sponsor decision for business purposes
- **Last updated:** 2020-11-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02936037

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02936037, "Effect of MD1003 in Progressive Multiple Sclerosis (SPI2)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02936037. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*